VolitionRx 'has a lot of shots on goal' as development of assays advances

Cameron Reynolds, president and chief executive of VolitionRx Ltd (NYSEAMERICAN: VNRX) discusses with Proactive's Andrew Scott the company's second quarter update and recent preliminary data from a study that showed their Nu.Q assay kits diagnosed men with aggressive prostate cancer with 94% accuracy.

Among the company’s recent wins is a sales agreement with Active Motif for an array of Research-Use-Only kits, the first of which, the Nu.Q Total assay kit is now on the market.

Additional advances include VolitionRx’s move to sign agreements to conduct two colorectal cancer research studies across Asia in collaboration with the National Taiwan University.

Quick facts: VolitionRx

Price: $4.18

Market Cap: $171.76 m


VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash. ''Total cash in hand that gives...

on 9/5/19

2 min read